1. Introduction {#sec1}
===============

The study of the stem cells potential has stimulated the onset of new areas, as the regenerative medicine and tissue bioengineering. Cell-based therapies to treat human diseases have become a clinical reality in the light of the advances in research with adult stem cells and embryonic stem cells, the two major divisions of stem cells. Recent works have shown that it is already possible to reprogram somatic cells into ones with similar characteristics to ESCs, being referred to as induced pluripotent stem cells (iPSCs). These cells are strong candidates to be applied in cellular therapy, requiring even more studies to master this new technology.

PubMed searches for publications with the exact terminology "stem cell therapy" indicate a strong growth in the number of publications in this area over the last 19 years, shown in [Figure 1](#fig1){ref-type="fig"}. In spite of the obvious importance of this issue, only few manuscripts appeared before 2000 years.

Aiming for a personalized cell therapy, some criteria or parameters must be observed. This paper will discuss some controversial issues of importance for achieving cell therapy safety and success. Particularly, the following aspects of stem cell biology will be presented: methods for stem cells culture, teratogenic or tumorigenic potential, cellular dose, proliferation, senescence, karyotyping, and immunosuppressive activity.

2. Cell Culture Free of Animal Components {#sec2}
=========================================

Methods of cell cultivation have been fundamental to physiological, biological, and pharmacological assessments at cellular and tissue levels \[[@B1]\], as well as to molecular studies. Besides enabling the production of biological components of human interest, such as vaccines and hormones, cell cultures help in the advancement of stem cell research by allowing the improvement of the stem cells for cellular therapy. The cultivation conventional system of mammalian cells is performed in an incubator at 37°C (5% CO~2~ and 95% O~2~). The composition of the culture medium is critical to the success of cell culture and the maintenance of cells for long periods *in vitro*, often requiring to be supplemented with other factors, such as serum. The most commonly used serum is fetal bovine serum (SFB) which is composed of a mixture of several substances in undefined concentrations as hormones, growth factors, vitamins, and other unknown substances \[[@B1]\].

The use of serum in culture media in research is associated with several problems such as limited availability of good fetal bovine serum suppliers, batch-to-batch variation causing inconsistency in both cell growth pattern and products formation and the risk of viral, mycoplasmal, and prions contamination, and interfering with the effect of hormones or growth factors upon studying their interaction with cells \[[@B2]--[@B4]\]. Due to the possible contamination of stem cells with bovine infectious agents and the concern of transmission of these agents to patients, plus the possibility of cultured cells to incorporate animal proteins that can provoke allergic reactions in humans \[[@B4]\], there is a growing concern and a consensus that research has to be done in order to establish new supplements and cultivation conditions for cell therapy, avoiding the use of animal-origin reagents in cell culture.

There are more than 100 serum-free culture medium formulations \[[@B5]\] with 4 basic types of culture medium \[[@B1]\]: (i) serum-free medium; containing small fractions of protein either from animal origin or from plant extracts which characterize it as a medium chemically undefined; (ii) protein-free medium; it has fractions of peptides (hydrolysed proteins) and is also considered to be a chemically undefined medium; (iii) animal- and human-derived components-free medium; it is not considered to be chemically defined, since it may contain bacteria, yeast hydrolysates, and plant extracts; (iv) chemically defined medium; it does not have protein, hydrolysed or any component of unknown composition. Hormones, animal or plant growth factors, as well as highly purified recombinant products may be supplemented in the culture medium.

Many research groups have been struggling to achieve the appropriate culture medium for cell therapy; however, many searches need to be performed to achieve this purpose.

3. Teratogenic or Tumorigenic Propriety of Stem Cells {#sec3}
=====================================================

The stem cells can be classified as embryonic (ESCs) and adult stem cells (ASCs). ESCs research reveals their enormous potential for differentiation and ability to originate almost all tissues of our body. The establishment of ESCs lines is problematic, since it involves ethical issues in relation to the destruction of embryos. According to the literature, there are several reports of ESCs transplants performed on animals, which resulted in the formation of teratomas on the recipient organism \[[@B6]--[@B14]\], which is undesirable for cellular therapy. Particularly, teratomas have been formed by hESC transplantation into the testis \[[@B15]--[@B17]\], kidney capsule \[[@B18]\], liver \[[@B19]\], hind leg muscle \[[@B20]--[@B23]\], and into the subcutaneous space \[[@B19], [@B24]\].

Numerous published reports have examined the potential of differentiated cell types derived from mouse and human ESCs to repair nonhuman target organs in intact animals \[[@B25]--[@B33]\]. Recent studies, however, have yielded both encouragement and caution, with restoration of function evident to some degree in many cases, but coexisting in others with the troubling finding that the grafts contained evidence of cancerous growth \[[@B8], [@B14], [@B34]--[@B38]\].

Kahan et al. \[[@B39]\] showed that the selection of embryonic stem cells presenting the markup SSEA1^−^SSEA3^−^EpCAM^+^, both mouse and human, resulted in eliminating the tumorigenic potential from differentiated ESC populations. Sorted cells do not form teratomas after transplantation into immunodeficient mice, but showed gene and protein expression profiles that are indicative of definitive endoderm cells. Sorted cells could be subsequently expanded *in vitro* and further differentiated to express key pancreas specification proteins. *In vivo* transplantation of sorted cells resulted in small, benign tissues that uniformly express PDX1. It represents one of transcripts expressed during gastrulation or early periods of endoderm development.

Adult stem cells have generated great interest among the scientific community devoid of their potential therapeutic applications for unmet medical needs. According to some studies, in addition to ESCs, some adult stem cells also form tumors when reintroduced into the organism. Recently, it was reported a case of a child with ataxia telangiectasia that developed multifocal brain and spinal cord tumors 4 years after treatment with human neural stem cells originating from at least two donors, even though the cells were relatively freshly derived from chromosomally normal fetuses \[[@B40]\]. Among ASCs, we highlight the hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) as those most well studied and reported in the scientific literature.

Obtaining the HSCs from bone marrow is an invasive and painful process for the patient. The HSCs are more restricted, as they have the capacity of proliferation and differentiation, resulting only in cells of the myeloid and lymphoid lineages. The transplant with HSCs must also be careful because it can result in graft-versus-host disease (GVHD) \[[@B41], [@B42]\]. This is a systemic syndrome that occurs in patients that receive immunocompetent lymphocytes. The pathophysiology involves an immune reaction between transplanted lymphocytes and development of an immune attack of the T cells from the donor to the host\'s cell, which differ from the former by histocompatibility antigens. It is, therefore, a primary complication of allogeneic bone marrow transplantation \[[@B41], [@B42]\]. The first three months after transplantation of HSCs can be marked by a greater number of complications due to direct toxicity of the conditioning, coupled with prolonged period of aplasia, infections, and acute GVHD. After this period and in the months ahead, complications are less frequent but also occur, as a result of chronic GVHD, with late damages to several organs and hematopoietic system \[[@B43]\]. For these reasons, HSCs should also be used with caution. In accordance with the literature, the HSCs obtained by ESCs differentiation can result in teratomas when reintroduced into the body. Its use in cell therapy should ensure that the transplanted cells will be free of residual teratogenic cells \[[@B44]--[@B47]\].

Besides the HSCs, there is another cell type present in the bone marrow which has great potential for cell therapy, the mesenchymal stem cells (MSCs). MSCs have been identified from various tissues in the past decade, including bone marrow, adipose tissue, umbilical cord, and dental pulp. The International Society for Cellular Therapy has recommended the following minimum criteria for defining multipotent human MSCs \[[@B48], [@B49]\]: (i) adherence to plastic under standard culture conditions; (ii) positive for expression of CD105, CD73, and CD90 and negative for expression of the hematopoietic cell surface markers CD34, CD45, CD11a, CD19 or CD79a, CD14 or CD11b, and histocompatibility locus antigen (HLA)-DR; (iii) under a specific stimulus, differentiation into osteocytes, adipocytes, and chondrocytes *in vitro*. To date, human bone marrow represents the major source of MSCs \[[@B50]--[@B54]\], and MSCs have potential to be expanded and cryopreserved for future use as an off-the-shelf therapy \[[@B55]\]. Currently, autologous MSCs derived from bone marrow have been applied for cell-based therapies, including the treatment of osteogenesis imperfecta, intracoronary transplantation in patients with acute myocardial infarction, and support of haematopoiesis \[[@B50], [@B51], [@B53], [@B54], [@B56]\]. Studies in mice show that MSCs are also involved in carcinogenesis. Houghton et al. \[[@B57]\] showed that chronic infection of C57BL/6 mice with *Helicobacter*, a known carcinogen, repopulated the stomach with bone-marrow-derived cells. It was observed that these cells progressed through metaplasia and dysplasia to intraepithelial cancer. These findings have broad implications for the multistep model of cancer progression, as they suggest that epithelial cancers can be originated from bone-marrow-derived sources \[[@B57]\]. Thus, a study of carcinogenic potential sources of many adults MSCs is prudent.

The reprogramming of somatic cells was a major advance in order to avoid ethical problems related to the destruction of the embryo, and this methodology has helped understand even more about pluripotency. There is an effort to improve the technique, since many use retroviral or lentiviral vectors for expression of genes related to embryonic transcription factors (NANOG, OCT4, and KFL4) besides c-Myc. The reprogrammed cells exhibit characteristics similar to embryonic stem cells, the ability to differentiate into many cell types, but there are also several reports of teratoma formation \[[@B58]--[@B60]\].

4. Appropriate Cellular Dose to Be Transplanted {#sec4}
===============================================

One of the major issues to be addressed is the cell dose to be transplanted into a patient, which would provide successful treatment. As well as medicines, there must be a correlation between cell number and the body weight of the patient. According to the literature, there is no consensus among researchers about the cell dose required.

Currently, the most used cells in cell therapy are hematopoietic stem cells present in umbilical cord blood (CB) and bone marrow and, in some cases, in the peripheral blood. Human umbilical cord blood has long been recognized as a rich source of primitive and committed hematopoietic progenitors. In addition, the general availability and the ease of procurement make cord blood a very attractive alternative source of transplantable hematopoietic tissue \[[@B61]\]. HSCs are contained within a population of mononuclear CD34+ antigen-expressing cells, which typically represent less than 1% of the total leukocytes in CB \[[@B62]\]. Research have suggested that, on the basis of the number of progenitor cells present in umbilical cord blood, it needs to be transplanted with restriction on children and some adults weighing less than 40 kg \[[@B63]--[@B65]\].

Jaime-Pérez et al. \[[@B66]\] analyzed 794 CB units in which the amount of CD34^+^ cells was determined by flow cytometry. Although there are not accepted universal guidelines, most Cord Blood Banks use the combination of product weight (volume) and total nucleated cell (TNC) count as the main selection factors for cryopreservation, requiring a TNC content from 6--10 × 10^8^ for storage \[[@B67]\] and a minimal volume between 40 and 60 mL \[[@B68]--[@B70]\]. The study showed that the amount of TNC is the best parameter that correlates with the contents of CD34+ cells, being in agreement with previous reports \[[@B71]--[@B73]\] and that all CB units having a TNC count of 8 × 10^8^ or more had the required CD34+ cell dose for patients weighing 10 kg or less.

Even in the face of such an impasse, the use of cord blood has been extended to include adults, allowing better definitions of cell dose limitations and thresholds \[[@B74]--[@B79]\]. The results of these transplants have helped to define a requirement for a minimum cell dose from 3 × 10^7^ to 3.5 × 10^7^ nucleated cells/kg in order to obtain acceptable clinical outcomes \[[@B80]\], and specifically, the CD34+ cell content has been shown to influence engraftment and survival after unrelated UCB transplantation, better predicting the hematopoietic potential of a CB unit was obtained after infused with 1.7 × 10^5^ CD34+ cells per kilogram of the recipient\'s body weight the threshold dose than nucleated cell content \[[@B81]\].

Nucleated cells can also be obtained from the bone marrow and peripheral blood. Hernigou et al. \[[@B82]\], aiming for autologous transplantation, calculated the number of medullary nuclear cells per kg of marrow using a formula that takes into account blood dilution. In each milliliter of aspirate, it was estimated that medullary cells were represented by the difference between the nuclear cell count in the aspirate and that in peripheral blood, which is assessed during general anesthesia. The number of nuclear cells of presumed medullary origin per kg is expressed as follows: *N*(10^8^/kg) = (*V* × NP)−(*V* − 100) × NS/P, where *V* is total volume of aspirate in mL, including the harvesting medium; NP is nuclear cell count per milliliter in the collection bag which leaves the operating room, including the harvesting medium; *V* − 100 is the exact volume of aspirate, after subtraction of the 100 mL of harvesting medium; NS is the nuclear cell count per milliliter of peripheral blood drawn during general anesthesia; *P* is patient\'s weight in kilograms. Thus, for these parameters researchers suggest a total final volume of 300 mL containing 14 × 10^6^ nuclear cells per milliliter, obtained from a 70 kg adult with a leucocyte count of 4 × 10^6^ per milliliter as determined under general anesthesia, it may be estimated that the medullary nuclear cell count is 5 × 10^7^ per kilograms, for a total of 0.35 × 10^10^ nuclear cells \[[@B82]\]. In case of allogeneic transplants, it is recommended to be obtained a number of nucleated cells greater than 2 × 10^8^/Kg. This way, when the weight of the donor is similar to the weight of the receptor, this value is obtainable by the aspiration of nearly 10 mL/kg of the weight of the donor, by volume of aspired bone marrow \[[@B83]\].

In peripheral blood, under normal conditions, there is a small number of stem cells (CD34+). Therefore, the use of this route to obtain stem cells for medullar transplant requires the prior mobilization of these cells from the bone marrow to the blood \[[@B84]\]. This mobilization is done by the administration of recombinant hematopoietic growth factor or colony-stimulating factor (CSF) to obtain a sufficient concentration of blood CD34^+^ cells in the blood and ensure the success of the transplantation \[[@B84], [@B85]\]. The optimal number of CD34+ cells for allogeneic transplantation is not well established and it is usually done with 4 to 6 × 10^6^ CD34+ cells/kg of the receiver\'s weight \[[@B86]--[@B89]\]. In autologous transplant, the recommendation is that the number of cells must be greater than 2 × 10^6^ CD34+ cells/kg of the patient\'s weight \[[@B90]\].

5. Proliferation, Senescence, and Karyotype {#sec5}
===========================================

The embryonic and adult stem cells may undergo symmetric cell divisions to self-renew or undergo terminal differentiation, or they may undergo asymmetric cell divisions to generate differentiated progeny as well as maintain a pool of stem cells. A dynamic balance between proliferation, survival, and differentiation signals ensures that an appropriate equilibrium between stem cells, precursor cells, and differentiated cells is maintained throughout development and adult life \[[@B91]\].

This renewal capacity is not a perfect process and the "daughter\'s cells" gradually lose the ability to proliferate, partly due to a gradual erosion of telomeres in each cell division. This phenomenon can be observed both *in vivo* and *in vitro*\[[@B92]--[@B95]\]. Telomeres are structures present at the end of eukaryotic chromosomes that protect chromosomes from degradation, fusion, and recombination. In mammalian cells, they consist of hexanucleotide (TTAGGG) repeats and several associated protein components. In the absence of compensatory mechanisms, dividing cells undergo gradual telomere reduction. When telomeres reach a critical degree of shortening, cells recognize this as DNA damage and initiate proapoptotic programs or enter senescence \[[@B96]\].

*In vivo*, as the body ages, the stock of stem cells in our body decreases, being perhaps the explanation for the failure of some organs repair during ageing. In studies with bone marrow conducted in over 1,000 patients \[[@B97]--[@B104]\], it was noted that the bone marrow cellularity: (a) decreases with increasing age and (b) decreases with the prevalence of connective tissue progenitors with increasing age in women. The total number of progenitors represents the product of the nucleated cells and the prevalence of progenitors in the aspirate plus a decline in the number of nucleated cells can be corrected by an increase of the volume aspirated.

Proliferation/expansion potential of hMSCs is affected by the *in vitro*culture conditions, which results in changing of cell/culture morphology. An interesting example is that under established *in vitro* conditions, hMSCs grow as a monolayer, but when cultured in hypoxic atmosphere, a condition found in many tumors *in vivo,*they continue to proliferate and the cell density increases, showing a 30-fold higher expansion rate \[[@B105]\]. The investigation of the proliferative potential of cells *in vitro*is necessary due to the possibility of tumor formation by some adult stem cells and especially embryonic stem cells. This process is a result of the loss of normal cellular control and is an initial aspect of cancerous tumor formation. It is important to note that most tumors arise from dividing populations of stem or precursor cells. Indeed, in the hematopoietic system each stage of stem cell to blast cell to be differentiated cell is associated with a leukemia or lymphoma \[[@B106]\]. The relative infrequency of transformation, however, suggests that the ability to self-renewing, surviving, proliferation, differentiation or transformation are closely regulated features. Thus, it commonly believed that the overall stem cell status in any self-renewing tissue is a dynamic balance between cell intrinsic and cell extrinsic factors. Furthermore, abnormalities in any of these stages will alter normal development or will affect cellular response to the normal aging process \[[@B91]\].

The cell proliferation also influences the karyotype of stem cells. In karyotypes of human mesenchymal stem cells (hMSCs), at least 30% of senescent hMSCs display trisomy of chromosome 8 \[[@B107]\]. hMSCs generally become polyploid (mainly tetraploid) at passage 20 becoming aneuploid afterwards \[[@B108]\]. During senescence, hMSCs deregulated genes were mainly found at the short arm chromosome region 4q22-q23, which inserted into immortal cells caused loss of proliferation. Senescence is also associated with upregulation of microRNAs, namely, hsa-mir-371, hsa-mir- 369-5P, hsa-mir-29c, hsa-mir-499, and hsa-let-7f, which causes a change in the methylation pattern \[[@B109]\]. Study with dental pulp stem cells revealed that about 70% of the cells exhibited karyotypic abnormalities including polyploidy, aneuploidy, and ring chromosomes. The heterogeneous spectrum of abnormalities indicated a high frequency of chromosomal mutations that continuously arise upon extended culture. These findings emphasize the need for the careful analysis of the cytogenetic stability of cultured hDSCs before they can be used in clinical therapies. With respect to therapy application, special attention should be given to hMSC epigenetic changes and the appearance of senescence that could result in genomic abnormalities, during culture.

Miura et al. \[[@B110]\] demonstrated that murine bone-marrow-derived mesenchymal stem cells (BMMSCs), after numerous passages, obtained unlimited population doublings and proceeded to a malignant transformation state, resulting in fibrosarcoma formation *in vivo*. Transformed BMMSCs colonized to multiple organs when delivered systemically through the tail vein. Fibrosarcoma cells formed by transformed BMMSCs contained cancer progenitors, which were capable of generating colony clusters *in vitro* and fibrosarcoma *in vivo* by the second administration. The mechanism by which BMMSCs transformed to malignant cells was associated with accumulated chromosomal abnormalities, gradual elevation in telomerase activity, and increased c-myc expression \[[@B110]\]. Although aneuploidy has long been associated with cancer, it has recently been observed in cultured pluripotent and neuronal stem cells as well as normal neuronal progenitors and primary cells from blastocysts, showing that the tendency to generate aneuploid cells may also be a normal feature of regenerative systems \[[@B110]--[@B112]\].

Cell transformation (spontaneous or artificial) is the process, initiated by at least 2 genetic events (mutations), by which cells gain immortality. First studies of spontaneous transformation claimed that unlike hMSCs, only murine MSCs can spontaneously transform in culture \[[@B113]\]. It was concluded that *in vitro* BM-hMSC expansion and their use in therapy is completely safe. But in parallel, Rubio et al. \[[@B107]\] demonstrated that after 4 to 5 months of *in vitro* culture, 50% of the postsenescent adipose tissue-derived mesenchymal stem cell (AThMSC) clones can escape the proliferation crisis, resume proliferation, lose contact inhibition, and become tumor-like transformed mesenchymal stem cells. It was argued nonetheless that the susceptibility to malignant transformation is dependent on hMSC origin, and that AThMSCs derived from poor fat tissue stem cell are more prone to transformation than BM hMSCs derived from stem cell-rich BM \[[@B114]\]. This argument was banned when BMhMSC clones were shown to spontaneously transform as well \[[@B115]\]. A 2-stage model of spontaneous transformation was proposed, according to which a senescence crisis with proliferation arrest always precedes the resumption of proliferation that occurs when hMSCs undergo spontaneous transformation \[[@B116]\]. This model was widely accepted and challenged only by Wang et al., who argued that spontaneous transformation may already occur as early as at hMSC isolation \[[@B117]\]. Spontaneously transformed hMSCs (transformed mesenchymal stem cells) are morphologically distinct from early passage hMSCs and senescent hMSCs \[[@B107]\]. Spontaneous transformation is accompanied by distinct transcriptomic changes. Cells bypass the senescence crisis and transform by upregulation of c-myc expression, repression of p16 levels, acquisition of telomerase activity, Ink4a/Arf locus deletion, and Rb hyperphosphorilation \[[@B116]\]. In additional experiments the same authors were unable to confirm the *in vitro*hMSC transformation, since after a senescent phase, the hMSC culture became exhausted and the *in vitro* hMSC spontaneous transformation they described was an artifact due to cross-contamination with HT1080 cell line \[[@B118]\].

The biggest challenge in the use of stem cells in cellular therapy is the ability to maintain genetic integrity during long-term cultivation, as well as their ability to differentiate. By successive passages *in vitro*, the karyotype needs to be numerically and structurally intact, conferring genomic stability to the cells that are going to be used in cellular therapy. Cultured human adult stem cells are particularly susceptible to the acquisition of chromosomal anomalies because they require significant cell expansion \[[@B119]--[@B122]\].

6. Immunosuppressive Activity {#sec6}
=============================

Recently, scientists have been discussing the contribution that stem cells offer which leads to functional improvement of organ and body structures observed in experiments *in vivo*. Among the topics discussed, this contribution would come from tissue regeneration, cell fusion, and new blood vessels formation. Lately, the observation of the rapid postoperative recovery and rapid reestablishment of inflammatory condition caught the attention of scientists and led to deepening in the study of the fourth restorative of stem cells characteristic, the immunomodulator aspect, taken within cell-cell contact and paracrine contexts.

Many reports have shown MSCs to display low immunogenicity and profound immunomodulatory and anti-inflammatory capabilities *in vitro*\[[@B123]--[@B125]\]. Furthermore, MSCs have been used to treat several animal and patient diseases, including graft-versus-host disease \[[@B126]\], rheumatoid arthritis \[[@B127], [@B128]\], autoimmune encephalomyelitis \[[@B129], [@B130]\], and systemic lupus erythematosus \[[@B131]\]. Apart from bone-marrow-derived MSCs, MSCs from dental tissues, that is, periodontal ligament stem cell \[[@B132], [@B133]\], stem cells from apical papilla, and gingiva-derived MSCs \[[@B134]\] also have been demonstrated to have immunomodulatory effects while inhibiting the proliferation and function of T lymphocytes.

Among the major works, there are those which seek to understand the mechanism by which stem cells immunomodulate investigating the interaction of these cells with specific cells and isolated from the immune system. Bartholomew et al. \[[@B135]\] demonstrated that the MSCs isolated from baboon suppressed the proliferation of lymphocytes in a mixed lymphocyte culture (MLC) stimulated with ConA, and this suppression was dose-dependent. In human MSCs (hMSCs), the same was observed by Aggarwal and Pittenger \[[@B136]\]; in PHA-induced proliferation T cells, the inhibition was 50% to 60%. Rasmusson et al. \[[@B137]\] showed that the hMSCs inhibited the lyses promoted by cytotoxic T lymphocytes and that these cells escaped from the lyses promoted by NK cells more efficiently than K562 lymphoma cells. When cocultivated with B cells, the MSCs did not inhibit, but neither promoted the B-cells proliferation \[[@B138]\].

The MSCs tend to alter soluble factors decreasing proinflammatory factors and increasing anti-inflammatory ones. Aggarwal and Pittenger \[[@B136]\] conducted a series of experiments with different immune system cells. Dendritic cells (DCs) type 1 cocultured with hMSCs decreased levels of lipopolysaccharide (LPS)-induced TNF-*α*; DCs type 2 cocultured with hMSC increased levels of IL-10 after LPS stimulus. The same results were observed with TH1 and TH2 cells. TH1 effector cells in the presence of hMSCs decrease in IFN-*γ*; TH2 in the presence of hMSCs increase IL-4 levels. Finally, hMSCs were cocultured with IL-2-stimulated NK cells, that resulted in a decrease in IFN-*γ*. The production of immunoglobulins is also affected in the presence of MSCs. It has been seen that the MSCs in contact with spleen mononuclear cells (MNCs) stimulated with LPS reduced the IgG production, and that this effect is LPS dose-dependent. With a strong LPS stimulus, the MSCs have led to a reduced production of IgG, but with a low stimulus, they have led to an increase in IgG production. With enriched B cells, there was an increase in IgG production when grown with LPS and this increased even more in the presence of MSCs. While these cocultures did not influence the levels of IL-2, they raised the levels of IL-6, in the presence or absence of LPS, an important interleukin for differentiation and production of immunoglobulin \[[@B138]\]. Other factors secreted in cultures with hMSCs, in addition to the IL-6, were observed such as IL-8, PGE2, and vascular endothelial growth factor (VEGF) \[[@B136]\].

Then, the question whether there is a molecule that can have a central influence on the whole process of immunomodulation performed by stem cells remains. Aggarwal and Pittenger \[[@B136]\] conducted an investigation of the involvement of PGE2 in coculture with human peripheral blood mononuclear cells (PBMCs). Using the indometacin, an inhibitor of PGE2, they observed an increase in PBMCs proliferation, the same behavior found when the PBMCs are not cocultured with MSCs. More specifically, it was noted the increase in TNF-*α* and IFN-*γ* from the activated DCs and T cells when the coculture with MSCs received PGE2 inhibitors. This gives an indication of which PGE2 is a candidate molecule capable of influencing many immunomodulators aspects. This finding is further reinforced with MSCs enhancement of PGE2 production when incubated with the proinflammatory recombinant cytokines TNF-*α* or IFN-*γ*, indicating a negative feedback stimulated by these cytokines.

Chan et al. \[[@B139]\] observed that the MSCs have APC (antigen-presenting cells) characteristic. In APC test, MSCs challenged with *C. albicans* and *T. toxoid* were cocultivated with activated CD4+ cells. As time went by, an increased IFN-*γ* concentration was observed. The authors found that the MHC II molecule has its expression decreased when the cells are in the presence of high concentrations of IFN-*γ*, while expression remains unchanged at low concentrations. Along with the increase in the IFN-*γ* concentration, a decrease in the CD4+ cells proliferation was observed. The question posed is how could MSCs act as APCs in a microenvironment of immune responses when IFN-*γ* levels are expected to be elevated? The authors proposed that MSCs possess the characteristic of PCA at a time limited to a period before the inflammatory response, where the concentration of IFN-*γ* is low. Locking the IFN-*γ* receptor (IFN*γ*RI) using an anti-IFN*γ*RI antibody, there was no expression of MHC II. At the same time, it was shown the need of the IFN*γ*RI activation to induce APC function in MSCs, where the MSCs treated with one control isotype played the role of APC increasing CD4+ cells proliferation and MSCs treated with anti-IFN*γ*RI did not promote the CD4+ cells proliferation. Since the expression of MHC II depends on the IFNgRI activation by IFN-*γ*, the MSCs\' APC role is only possible moments before the IFN-*γ* levels increase during the immune process and once raised, the MSCs modulate to an anti-inflammatory function \[[@B140], [@B141]\]. Ryan et al. \[[@B142]\] reported that MSCs stimulated with IFN-*γ* increased the HGF and TGF-*β*1 production without changing the levels of IL-10. Human IL-10, TGF-*β*1, and HGF are known to have immunomodulatory properties. These cytokines have shown to reduce the proliferation of PBMCs in MLC test. Another molecule that suppresses the proliferation of PBMCs by MSCs stimulated with IFN-*γ* is the indoleamine 2,3,dioxygenase (IDO), which occurs via the accumulation of kynurenine, a metabolite of tryptophan \[[@B142]\].

The immunomodulatory capacity of MSCs is not only in the suppression of cell proliferation caused by an immune reaction, it extends to the change of cell types linked to anti-inflammatory processes. The cocultivation of MSCs with CD4+ cells, resulted in a CD25 and FoxP3 increased expression, molecules that characterize Treg cells. The soluble factors such as IL-10, TGF-*β*1, and PGE2 alone did not promote the increase of positive cells for the markers mentioned in culture of CD4+ cells alone. However, cultures of PBMCs that received these molecules showed an increase in the CD25 and FoxP3 expression, without the presence of MSCs, indicating that probably other cells of the immune system aided in induction of Tregs. The cocultivation of MSCs with CD4+ cells in the presence of TGF-*β* and PGE2 inhibitors has decreased the expression of FoxP3 and CD25 proteins on CD4+. This indicates that the cell-cell contact and these factors are required to induce Tregs by MSCs \[[@B143]\].

Aggarwal and Pittenger \[[@B136]\] proposed a model of MSCs interaction with various immune cells and suggested that the MSCs inhibit or limit the inflammatory response, besides promoting mitigating paths and anti-inflammatory effect. When the MSCs are present in an inflammatory environment created artificially (*in vitro*), they change the immune response by inhibiting DC1 inflammatory signaling (decreasing IL-12 and TNF-*α* secretion) and promoting DC2 anti-inflammatory signaling (increasing the secretion of IL-10). Furthermore, when the immature effector T cells are present, the MSCs may interact with and inhibit the development of TH1 and NK signaling (decreasing the secretion of INF-*γ*) and promoting TH2 anti-inflammatory signaling and Treg suppressive effect (increasing IL4 secretion). Yagi et al. \[[@B144]\] proposed a model for the interactions of cytokines which MSC express MHC-II and function as APCs, at low levels of IFN-*γ*. At high levels of IFN-*γ*, MHC-II is downregulated MHC-II and B7-H1 is upregulated. IFN-*γ* and TNF-*α* individually stimulate MSCs to upregulate PGE2, COX-2, and/or IDO. These mediators can inhibit function of immune cells such as T cell, NK cell, and DC.

Other sources of stem cells have the immunomodulator aspect have been investigated. Pierdomenico et al. \[[@B145]\] compared MSCs with dental pulp stem cells (DPSCs) in their immunosuppressive capacity. The authors found that the DPSCs are more immunomodulatory than MSCs. Stem cells from human exfoliated deciduous teeth (SHEDs) are also shown to be more efficient in inhibiting the proliferation of Th17 cells than MSCs \[[@B146]\].

The inhibitory effect of the MSCs over the MLC is not dependent on the origin of the MSCs (autogenous or allogeneic), that can be stated as the most important result of this context \[[@B135], [@B140]\]. This immunomodulatory effect remains in those cells even after differentiation, as shown *in vitro*, by Le Blanc et al. \[[@B140]\]. MSCs which were induced into adipogenesis, chondrogenesis, and osteogenesis did not express class II MHC. The differentiated MSCs continued to inhibit the T lymphocytes proliferative response, being this feature improved when treated with INF-*γ* \[[@B141]\]. This could show that those cells may be transplanted between patients with different HLA.

As previously observed, apparently, the immunomodulatory property of the stem cells is dependent on the environment in which those are inserted. Seemingly, the stem cells have a homeostatic effect and also possess APC characteristics. During the initial part of an inflammatory process, the MSCs increase their potential of antigen presenting in order to fight infection. However, as time progresses, the pro-inflammatory environment immunomodulates the MSCs in such a way that those assume an anti-inflammatory character, this feature seems to regulate the whole pro-inflammatory medium towards homeostasis.

Recently, it has been published a creative strategy of dealing with autoimmune diseases. Zhao et al. \[[@B147]\] applied this strategy directly on type I diabetes patients. These authors developed an apparatus, which enclose nine plates, piled upon each other, where the umbilical cord stem cells (CB-SCs) were seeded. The patient\'s circulatory system was connected to a cell sorter in order to isolate lymphocytes, which after collected were transferred directly to the equipment containing the CB-SCs. After 8- to 10-hour procedure, the lymphocytes were reintroduced into the patient, in a closed circuit. The procedure\'s result was assessed by measuring the C-peptides levels (a product yielded during the biosynthesis of insulin, which indicates *β*-cells functioning). Patients treated have shown increasing levels of C-peptide and reduction in the mean values of glycated hemoglobin A1C (HbA1C). These results are promising, since the patients who would not have residual function on the *β*-cells began to show functional improvement, demonstrated by the glucose-stimulated C-peptide levels, even after 40 weeks past the procedure. It was also shown an increase in the Treg cells population and reestablishment of the TH1-, TH2-, and TH3-related cytokines levels. The data indicates that the immune system cells were reprogrammed to recognize the patient\'s tissue as its own. This statement is reinforced by the evidence that patients with no residual *β*-cell function had the metabolism control improved, which indicates reduction on autoimmunity and pancreatic islets recovery.

7. Conclusion {#sec7}
=============

Advances in researches aiming for cellular therapy have brought important impacts on the medical field with promises of treatment of many human diseases, and in the biotechnology area with the generation of various products and biomaterials. However, as reported here, it was shown that for cell therapy success and safety, it is necessary to overcome certain limitations, such as the use of animal component in cell cultivation, for instance, the fetal bovine serum. Choosing the stem cells that will be used in cellular therapy is also very important in terms of clinical safety for the patient, since the scientific literature has been reporting the teratogenic potential of embryonic stem cells and iPSCs, and possible adult stem cell lines. In addition to the choice of stem cells, another parameter is the appropriate cell dose for a successful treatment. The cells, most commonly reported in scientific studies, are the haematopoietic origin cells. Based on these reports, we have shown that there is no consensus yet on the amount of stem cells to be transplanted and the patient\'s body weight. The hematopoietic stem cells are not able to be expanded *in vitro*, which does not happen with adult stem cells from nonhematopoietic origin, that can be expanded even in low passages in huge quantities, bypassing the current problem of haematopoietic cells that can only be transplanted in individuals with less than 40 kg on the basis of the quantity of CD34+ progenitors cells. Besides the cellular type and dosage, the proliferation and senescence should be investigated before transplantation because there are reports that chromosomal changes may occur during *in vitro* cultivation, and such changes could affect the cells engraftment. Therefore, the genomic stability must be considered by conducting karyotype analysis to ensure stability and normality at the occasion of transplantation, although other factors such as miRNA and chromatin changing are a challenge for the future. The use of cells which show immunosuppressive and anti-inflammatory activities is also interesting for cellular therapy, since they overcome the current compatibility problem between individuals and may reinforce the therapeutic success. Summarizing, cell therapy safety and success are bound to be achieved by the characterization of stem cells before those critical issues.
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